{
    "clinical_study": {
        "@rank": "115830", 
        "arm_group": {
            "arm_group_label": "Triciribine and Carboplatin Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Phase I/II Clinical Trial Doses: The starting dose for this phase I study (dose level 1) will be TCN 15 mg/m2 on days 1, 8 and 15 and Carboplatin AUC 5. TCN will be escalated to 25, 35, then 45 mg/m2 if dose limiting toxicities (DLTs) are not encountered. Phase II: Treat 18 additional patients at the recommended Phase II dose of triciribine + carboplatin to confirm safety and tolerability and assess response rate and Progression Free Survival (PFS)"
        }, 
        "brief_summary": {
            "textblock": "The main purpose of this study is to see if we can select patients based on their cancer\n      characteristics, to determine if Triciribine (TCN) and carboplatin are safe and tolerable\n      when given together, and to determine if this combination of drugs can help people with\n      recurrent ovarian cancer."
        }, 
        "brief_title": "Triciribine and Carboplatin in Ovarian Cancer", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "A portion of the patient's cancer tissue, previously removed, will be analyzed for a\n      specific protein (phosphorylated BCL-2 antagonist of cell death).  If the patient is found\n      to have high levels of this protein in their tumor, they may qualify to be in the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 18 years of age\n\n          -  Histologically confirmed, measurable or non-measurable, recurrent or persistent,\n             platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma\n\n          -  At least one prior regimen of chemotherapy, with no maximum number of chemotherapy\n             cycles\n\n          -  A serum creatinine \u2264 1.5 mg% obtained \u2264 2 weeks prior to entry\n\n          -  Adequate hematologic reserve obtained \u2264 2 weeks prior to entry: leukocytes \u2265 3,000\n             mm^3; absolute neutrophil count \u2265 1500 mm^3; platelets \u2265 100,000 mm^3\n\n          -  Adequate hepatocellular function: AST (SGOT) and ALT (SGPT) \u2264 3x upper limit of\n             normal within institutional limits; bilirubin \u2264 1.5 mg/dl\n\n          -  Gynecologic Oncology Group (GOG) Performance Status of 0, 1, or 2\n\n          -  Life expectancy of at least 90 days\n\n          -  The patient should be off chemotherapy, biologic therapy and radiation for 28 days.\n\n          -  Neuropathy (sensory and motor) less than or equal to grade 1 per Common Toxicity\n             Criteria (CTC) version 4\n\n          -  Patient tumors must demonstrate high (>median) phospho-BAD levels on\n             immunohistochemical-based analyses.\n\n        Exclusion Criteria:\n\n          -  Prior TCN-PM therapy\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to TCN-PM\n\n          -  Patients must be disease-free of prior invasive malignancies for >2 years with the\n             exception of basal cell or squamous cell carcinoma of the skin.\n\n          -  Inability to give informed consent"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01690468", 
            "org_study_id": "MCC-17035"
        }, 
        "intervention": [
            {
                "arm_group_label": "Triciribine and Carboplatin Treatment", 
                "description": "Triciribine (15, 25, 35, or 45 mg/m2) on days 1, 8, 15 every 21 days. To be given as a 60 minute IV infusion.", 
                "intervention_name": "Triciribine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "triciribine phosphate monohydrate", 
                    "TCN", 
                    "TCN-PM", 
                    "AKT inhibitor"
                ]
            }, 
            {
                "arm_group_label": "Triciribine and Carboplatin Treatment", 
                "description": "Carboplatin will be administered on day 1 every 21 days, as a 30 minute IV infusion after completion of TCN.", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Paraplatin\u00ae", 
                    "NSC #241240"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Carboplatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 13, 2014", 
        "link": {
            "description": "Moffitt Cancer Center Clinical Trials website", 
            "url": "http://www.moffitt.org/research--clinical-trials/clinical-trials"
        }, 
        "location": {
            "contact": {
                "email": "amber.herschberger@moffitt.org", 
                "last_name": "Amber Herschberger", 
                "phone": "813-745-7272"
            }, 
            "facility": {
                "address": {
                    "city": "Tampa", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33612"
                }, 
                "name": "H. Lee Moffitt Cancer Center and Research Institute"
            }, 
            "investigator": [
                {
                    "last_name": "Patricia L. Judson, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Sachin Apte, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jesus Gonzalez-Bosquet, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Johnathan M. Lancaster, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Said M. Sebti, Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Robert M. Wenham, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Leveraging a Clinico-Genomic Database to Match Patients to a Trial of Triciribine and Carboplatin: Changing Paradigms in Ovarian Cancer Clinical Research", 
        "overall_official": {
            "affiliation": "H. Lee Moffitt Cancer Center and Research Institute", 
            "last_name": "Patricia L. Judson, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the maximum tolerated dose of TCN-PM when combined with carboplatin in a Phase I clinical trial of biomarker-selected women with platinum-resistant, recurrent or persistent epithelial ovarian, fallopian tube and primary peritoneal cancer (OVCA).", 
            "measure": "Maximum Tolerated Dose (MTD)", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01690468"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The best overall response is the best time point response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest sum recorded since baseline).\nComplete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10mm.\nPartial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.\nResponse and progression will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST version 1-1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.", 
                "measure": "Overall Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Progression-Free Survival (PFS) is defined as the duration of time from study entry to time of progression or death, whichever occurs first.\nProgressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).\nResponse and progression will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST version 1-1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.", 
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Stable Disease (SD): Neither sufficient shrinkage to qualify for Partial Response (PR) nor sufficient increase to qualify for Progressive Disease (PD), taking as reference the smallest sum diameters while on study.\nResponse and progression will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST version 1-1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.", 
                "measure": "Duration of Stable Disease (SD)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "H. Lee Moffitt Cancer Center and Research Institute", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Department of Defense", 
                    "agency_class": "U.S. Fed"
                }, 
                {
                    "agency": "Cahaba Pharmaceuticals", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "H. Lee Moffitt Cancer Center and Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}